Chemosensitization With Plerixafor Plus G-CSF in Relapsed or Refractory Acute Myeloid Leukemia.

Trial Profile

Chemosensitization With Plerixafor Plus G-CSF in Relapsed or Refractory Acute Myeloid Leukemia.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 06 Apr 2017

At a glance

  • Drugs Plerixafor (Primary) ; Cytarabine; Etoposide; Filgrastim; Mitoxantrone
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 14 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 19 Mar 2015 Planned End Date changed from 1 Nov 2014 to 1 Sep 2015as per Clinicaltrials.gov record.
    • 27 Feb 2014 According to ClinicalTrials.gov record, planned end date changed from 1 Jun 2016 to 1 Nov 2014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top